{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:16:20Z","timestamp":1740176180412,"version":"3.37.3"},"reference-count":26,"publisher":"Central Research Institute for Epidemiology","issue":"2","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["virusjour.crie.ru"],"crossmark-restriction":false},"short-container-title":["Problems of Virology"],"abstract":"<jats:p>Objectives. The HTLV-1 infection persists for life, remaining as asymptomatic viral reservoirs in most patients, ensuring the chain of transmission, but around 4% develop adult T-cell leukemia\/lymphoma (ATLL). HTLV-1 is an oncogenic retrovirus that transforms CD4+ T lymphocytes and deregulates the lymphoproliferative pathways that contribute to the development of ATLL. To achieve cell transformation, most oncogenic retroviruses use proto-oncogene capture transduction, with proviral integration disrupting the expression of tumor suppressors or proto-oncogenes.\r\nThe aim. We conducted this study on the prevalence of HTLV-1 infection in blood donors to expand the HTLV-1 database, assess the risk of transmission via blood products, as well as evaluate the risk of persistent infection or development of neoplastic diseases in HTLV-1 carriers.\r\nMaterials and methods. This is a cross-sectional study of blood donors of all categories. For this study, 265 blood donors were recruited at the Centre National de Transfusion Sanguine in Brazzaville. After testing for HTLV-1 antibodies by ELISA, proviral DNA was extracted from all ELISA-positive samples for detection by nested PCR, followed by RT qPCR using specific primers p53 and c-myc for gene expression.\r\nResults. 20\/265 were positive for anti-HTLV-1 antibody, 5 donors were positive for proviral DNA. The prevalence of HTLV-1 was 1.8%. All HTLV-1-positive donors were male (1.8%), with a positive correlation (p = 0.05); the 1.1% of positive donors were regular, with the majority aged between 31 and 45 years (1.5%), and concubine donors were the most frequent (1.1%). All samples showed normal expression of the p53 and c-myc genes.\r\nConclusion. The prevalence, though low, remains a serious problem. No abnormal p53 or c-myc gene expression was detected in HTLV-1-positive donors, which could mean that none of the T lymphocytes in these donors had been transformed by HTLV-1.<\/jats:p>","DOI":"10.36233\/0507-4088-199","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T19:04:48Z","timestamp":1715022288000},"page":"127-133","update-policy":"https:\/\/doi.org\/10.36233\/0372-9311-crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Gene expression profiling of &lt;i&gt;p53&lt;\/i&gt; and &lt;i&gt;c-myc&lt;\/i&gt; in HTLV-1 positive blood donors in Congo"],"prefix":"10.36233","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5505-2145","authenticated-orcid":false,"given":"Patrina Joseph","family":"Iloukou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-5133","authenticated-orcid":false,"given":"Anicet L.M.","family":"Boumba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4838-2270","authenticated-orcid":false,"given":"Freddy S.","family":"Pouki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9474-7989","authenticated-orcid":false,"given":"Norvi R. B.","family":"Massengo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5402-9013","authenticated-orcid":false,"given":"Ragive P.","family":"Takale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6764-7122","authenticated-orcid":false,"given":"Donatien","family":"Moukassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-0270","authenticated-orcid":false,"given":"Moulay M.","family":"Ennaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22004","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Seitz R., Heiden M. Quality and safety in blood supply in 2010. Transfus. Med. Hemother. 2010; 37(3): 112\u20137. https:\/\/doi.org\/10.1159\/000314497","DOI":"10.1159\/000314497"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Laperche S., Lefr\u00e8re J.J., Morel P., Pouchol E., Pozzetto B. Blood transfusion: control of infectious risks. Presse Med. 2015; 44(2): 189\u201399. https:\/\/doi.org\/10.1016\/j.lpm.2014.06.034 (in French)","DOI":"10.1016\/j.lpm.2014.06.034"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Coffin J.M. The discovery of HTLV-1, the first pathogenic human retrovirus. Proc. Natl. Acad. Sci. U S A. 2015; 112(51): 15525\u20139. https:\/\/doi.org\/10.1073\/pnas.1521629112","DOI":"10.1073\/pnas.1521629112"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ampofo W., Nii-Trebi N., Ansah J., Abe K., Naito H., Aidoo S., et al. Prevalence of blood-borne infectious diseases in blood donors in Ghana. J. Clin. Microbiol. 2002; 40(9): 3523\u20135. https:\/\/doi.org\/10.1128\/JCM.40.9.3523-3525.2002","DOI":"10.1128\/JCM.40.9.3523-3525.2002"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Diop S., Calattini S., Abah-Dakou J., Thiam D., Diakhat\u00e9 L., Gessain A. Seroprevalence and molecular epidemiology of human T-Cell leukemia virus type 1 (HTLV-1) and HTLV-2 in blood donors from Dakar, Senegal. J. Clin. Microbiol. 2006; 44(4): 1550\u20134. https:\/\/doi.org\/10.1128\/JCM.44.4.1550-1554.2006","DOI":"10.1128\/JCM.44.4.1550-1554.2006"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Arisawa K., Soda M., Endo S., Kurokawa K., Katamine S., Shimokawa I., et al. Evaluation of adult T-cell leukemia\/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int. J. Cancer. 2000; 85(3): 319\u201324. https:\/\/doi.org\/10.1002\/(sici)1097-0215(20000201)85:3<319::aid-ijc4>3.0.co;2-b","DOI":"10.1002\/(SICI)1097-0215(20000201)85:3<319::AID-IJC4>3.0.CO;2-B"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Tamaki K., Mera H., Takeshita S., Fujioka S., Goto M., Matsumoto T., et al. A refractory human T-cell leukemia virus type 1-associated myelopathy\/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia\/lymphoma: A case report and review of the literature. Medicine (Baltimore). 2021; 100(40): e27450. https:\/\/doi.org\/10.1097\/MD.0000000000027450","DOI":"10.1097\/MD.0000000000027450"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Johnson J.M., Harrod R., Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia\/lymphotropic virus Type-1 (HTLV-1). Int. J. Exp. Pathol. 2001; 82(3): 135\u201347. https:\/\/doi.org\/10.1046\/j.1365-2613.2001.00191.x","DOI":"10.1046\/j.1365-2613.2001.00191.x"},{"key":"ref9","unstructured":"Reid R.L., Lindholm P.F., Mireskandari A., Dittmer J., Brady J.N. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene. 1993; 8(11): 3029\u201336."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005; 24(39): 6058\u201368. https:\/\/doi.org\/10.1038\/sj.onc.1208968","DOI":"10.1038\/sj.onc.1208968"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Carneiro-Proietti A.B., Catalan-Soares B.C., Castro-Costa C.M., Murphy E.L., Sabino E.C., Hisada M., et al. HTLV in the Americas: challenges and perspectives. Rev. Panam. Salud. Publica. 2006; 19(1): 44\u201353. https:\/\/doi.org\/10.1590\/s1020-49892006000100007","DOI":"10.1590\/S1020-49892006000100007"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Murphy E.L., Wilks R., Hanchard B., Cranston B., Figueroa J.P., Gibbs W.N., et al. A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica. Int. J. Epidemiol. 1996; 25(5): 1083\u20139. https:\/\/doi.org\/10.1093\/ije\/25.5.1083","DOI":"10.1093\/ije\/25.5.1083"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Desrames A., Cassar O., Gout O., Hermine O., Taylor G.P., Afonso P.V., et al. Northern African strains of human T-lymphotropic virus type 1 arose from a recombination event. J. Virol. 2014; 88(17): 9782\u20138. https:\/\/doi.org\/10.1128\/JVI.01591-14","DOI":"10.1128\/JVI.01591-14"},{"key":"ref14","unstructured":"Develoux M., Dupont A., Meynard D., Delaporte E. A case of tropical spastic paraparesis associated with HTLV1 in the Niger Republic. Med. Trop. (Mars). 1996; 56(1): 100\u20131. (in French)"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gessain A., Cassar O. HTLV-1 world distribution and estimation of the number of asymptomatic infected carriers. Retrovirology. 2014; 11(Suppl. 1): O14. https:\/\/doi.org\/10.1186\/1742-4690-11-S1-O14","DOI":"10.1186\/1742-4690-11-S1-O14"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Alessio L., Minichini C., Starace M., Occhiello L., Caroprese M., Di Caprio G., et al. Low prevalence of HTLV1\/2 infection in a population of immigrants living in southern Italy. PLoS Negl. Trop. Dis. 2018; 12(6): e0006601. https:\/\/doi.org\/10.1371\/journal.pntd.0006601","DOI":"10.1371\/journal.pntd.0006601"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Dumas M., Houinato D., Verdier M., Zohoun T., Josse R., Bonis J., et al. Seroepidemiology of human T-cell lymphotropic virus type I\/II in Benin (West Africa). AIDS Res. Hum. Retroviruses. 1991; 7(5): 447\u201351. https:\/\/doi.org\/10.1089\/aid.1991.7.447","DOI":"10.1089\/aid.1991.7.447"},{"key":"ref18","unstructured":"Gessain A., Fretz C., Koulibaly M. Evidence of HTLV-II infection in Guinea, West Africa. J. Acquir. Immune Defic. Syndr. (1988). 1993; 6(3): 324\u20135."},{"key":"ref19","unstructured":"Terry A.A., Olusoga O.D., Oluremi A..S, Okanlawon B.M., Uche L.N., Muibi F.A. Seroprevalence of HTLV-I\/II amongst Blood Donors in Osogbo, Nigeria. Sudan J. Med. Sci. 2011; 6(3): 177\u201382."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Uchenna Tweteise P., Natukunda B., Bazira J. Human T-cell lymphotropic virus types 1 and 2 seropositivity among blood donors at Mbarara regional blood bank, South Western Uganda. Leuk. Res. Treat. 2016; 1675326. https:\/\/doi.org\/10.1155\/2016\/1675326","DOI":"10.1155\/2016\/1675326"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bmt G. Human T-cell lymphotropic virus types 1 and 2 antibodies seroprevalence among blood donors at national public health blood bank, Khartoum\u2013Sudan 2019. J. Med. Sci. Res. 2020; 8(3): 100\u20134.","DOI":"10.17727\/JMSR.2020\/8-14"},{"key":"ref22","unstructured":"Mayakia P., Boumba A., Malonga G., Pouki F., Donatien M., Ennaji M.M. Epidemiological profile and seroprevalence of Human T-Lymphotropic Virus type 1 among blood donors in Pointe-Noire, Congo. Teikyo Med. J. 2022; 45(07): 6959\u201366."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Angounda B.M., Bokilo Dzia A., Niama F., Atipo Ibara B.I., Kobawila S.C., Ibara J.R. \u00c9valuation de la strat\u00e9gie de d\u00e9pistage du virus de l\u2019h\u00e9patite B chez les donneurs de sang \u00e0 Brazzaville. Transfusion Clinique et Biologique. 2015; 22(4): 229. https:\/\/doi.org\/10.1016\/j.tracli.2015.06.045","DOI":"10.1016\/j.tracli.2015.06.045"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Malonga G.A., Dienta S., Traore F.T., Maiga Z., Ba A., Faye O., et al. Human Herpesvirus 8 seroprevalence among blood donors in Mali. J. Med. Virol. 2022; 94(9): 4554\u20138. https:\/\/doi.org\/10.1002\/jmv.27850","DOI":"10.1002\/jmv.27850"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"de Lima W.M., Esteves F.A., Torres Mdo C., Pires E.S. Prevalence of human T-cell lymphotropic virus types 1 and 2 in blood donors of the Caruaru Blood Center (Hemope). Rev. Bras. Hematol. Hemoter. 2013; 35(4): 268\u201371. https:\/\/doi.org\/10.5581\/1516-8484.20130061","DOI":"10.5581\/1516-8484.20130061"},{"key":"ref26","unstructured":"Urwijitaroon Y., Barusrux S., Puapairoj C., Romphruk A., Khampeera P. Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance. J. Med. Assoc. Thai. 1997; 80(Suppl. 1): S102\u20135."}],"container-title":["Problems of Virology"],"original-title":[],"link":[{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16153\/876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/viewFile\/16153\/876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T19:05:10Z","timestamp":1715022310000},"score":1,"resource":{"primary":{"URL":"https:\/\/virusjour.crie.ru\/jour\/article\/view\/16153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,5,6]]}},"URL":"https:\/\/doi.org\/10.36233\/0507-4088-199","relation":{},"ISSN":["2411-2097","0507-4088"],"issn-type":[{"type":"electronic","value":"2411-2097"},{"type":"print","value":"0507-4088"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}